Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
The myeloproliferative disorders polycythaemia vera (PV), essential thombocythaemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic progenitors. The genetic cause of these diseases was not known until 2005, when several independent groups demonstrated that most patients with PV, ET and PMF acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F). These discoveries have changed the landscape for diagnosis and classification of PV, ET and PMF, and show the ability of genomic technologies to identify new molecular targets in human malignancies with pathogenetic, diagnostic and therapeutic significance.
Levine
Ross L
RL
Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02155, USA.
Pardanani
Animesh
A
Tefferi
Ayalew
A
Gilliland
D Gary
DG
D004789:Enzyme Activation; D005544:Forecasting; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000502:physiology; D009196:Myeloproliferative Disorders / Q000235:genetics* / Q000628:therapy*; D017354:Point Mutation; D015398:Signal Transduction; D015533:Transcriptional Activation
D053614:Janus Kinase 2